News and Events

Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients

19 November 2023

This study has analysed the transcriptomic and immune-metabolic profiles of Dendritic Cells (DCs) from 35 subjects enrolled in a trial of Dendritic Cells (DC) vaccines in late-stage melanoma. The authors conclude that the metabolic profile of DC is tightly associated with the immunostimulatory potential of DC vaccines from cancer patients, and they link phenotypic and functional metabolic changes to immune signatures that correspond to suppressed DC differentiation.

International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989-2020

17 November 2023

The purpose of this recent study was to compare the trends in incidence rates of cutaneous squamous cell carcinoma (cSCC) and melanoma, to provide insights into changing patterns of exposure to ultraviolet radiation. The study concludes that despite concerted international efforts to preserve the ozone layer over the past four decades resulting in significant reductions in surface UV-B at mid-latitudes, the incidence of skin cancer, particularly cSCC, continues to rise in those regions. 

Decoding the metastatic potential and optimal postoperative adjuvant therapy of melanoma based on metastasis score

17 November 2023

Authors of this recent study conducted comprehensive analyses of melanoma metastases using bulk and single-cell RNA sequencing data, enabling the construction of a metastasis score (MET score) through diverse machine-learning algorithms.The study concludes that the MET score is effective in predicting melanoma metastatic potential. For patients with low MET scores, a PD-1 therapy may be a potential treatment strategy to inhibit metastasis. Patients with high MET scores may benefit from combination therapies.

Poor compliance (except for teledermatology response rates) of melanoma diagnosis and treatment timeliness with MelNet Quality Statements

15 November 2023

The aim of this recent study was to assess compliance of melanoma diagnosis and treatment timeliness with the MelNet Quality Statements at Waikato Hospital and in primary care for melanoma and melanoma in situ (MIS). The studu concludes that for 43 melanomas and 105 MIS, compliance across all melanoma services was poor, except for teledermatology response rates (100% compliance). From referral to first cancer treatment (Statement 2.1.1), compliance was 50% in general practice and 7.7% in Waikato Hospital. Histopathological reporting delays were also identified.

Cancer Society's National Grant Round 2024 now open - including funding for melanoma research

9 November 2023

The Cancer Society of New Zealand (Te Kāhui Matepukupuku o Aotearoa) has announced that the 2024 National Grant Round is now open. The aim of the National Grant Round is to fund high-quality research across the cancer continuum (including prevention, diagnosis, treatment, and supportive care).  Specific funding is available for Melanoma research, and the Cancer Society encourage applications in this research area. 

Nivolumab and relatlimab: Manageable safety profile, durable clinical activity in proportion of patients with heavily pretreated advanced melanoma with prior progression on anti–PD-(L)1-containing regimens

19 October 2023

RELATIVITY-020 studied the safety of nivolumab and relatlimab in patients whose disease progressed on anti-PD-(L)1 treatments. The study concludes that nivolumab and relatlimab had a manageable safety profile and demonstrated durable clinical activity in a proportion of patients with heavily pretreated advanced melanoma with prior progression on anti–PD-(L)1-containing regimens.